|
06 Nov 2020 |
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
|
|
06 Nov 2020 |
Celltrion presents efficacy and safety data for potential COVID-19 treatment candidate CT-P59 in patients with mild symptoms
|
|
06 Nov 2020 |
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
|
|
05 Nov 2020 |
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
05 Nov 2020 |
Janssen Seeks Expanded Use of DARZALEX®▼ (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Light Chain (AL) Amyloidosis
|
|
05 Nov 2020 |
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
|
|
03 Nov 2020 |
Celltrion Healthcare Presents Positive Top-Line Efficacy and Safety Results for CT-P17 in the Treatment of Rheumatoid Arthritis
|
|
02 Nov 2020 |
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
|
|
02 Nov 2020 |
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy
|
|
02 Nov 2020 |
Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
|
|
02 Nov 2020 |
Jounce Therapeutics Announces Update on Vopratelimab Program
|
|
02 Nov 2020 |
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
|
|
31 Oct 2020 |
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira^® in Moderate-to-Severe Psoriasis Patients
|
|
30 Oct 2020 |
OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation
|
|
30 Oct 2020 |
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
|
|
30 Oct 2020 |
REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements
|
|
30 Oct 2020 |
Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan for Anti-CGRP Antibody Galcanezumab
|
|
29 Oct 2020 |
Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
|
|
29 Oct 2020 |
Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
|
|
29 Oct 2020 |
FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
|
|
29 Oct 2020 |
Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC
|
|
29 Oct 2020 |
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
|
|
29 Oct 2020 |
Fasenra eliminated oral corticosteroid use in a majority of OCS-dependent patients with asthma in PONENTE Phase IIIb trial
|
|
28 Oct 2020 |
Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications
|
|
28 Oct 2020 |
ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
|
